Our Pipeline

Current VDPHL01 Clinical Trials

PRECLINICALPHASE 1PHASE 2PHASE 3FILED

Study 302

Phase 2/3 trial evaluating VDPHL01 in males with pattern hair loss

PHASE 3

Phase 3 registration-directed study in males
Parallel in-trial Phase 2 component to further assess patient reported outcome (PRO) endpoints in Studies 302 & 304
Fully enrolled, with 6-month topline Phase 2/3 readout completed in April 2026

Learn more

PRECLINICALPHASE 1PHASE 2PHASE 3FILED

Study 304

Phase 3 trial evaluating VDPHL01 in males with pattern hair loss

PHASE 3

Confirmatory Phase 3 registration- directed study in males
Fully enrolled with 6-month topline Phase 3 readout anticipated in H2 2026

PRECLINICALPHASE 1PHASE 2PHASE 3FILED

Study 306

Phase 2/3 trial evaluating VDPHLO1 in females with pattern hair loss

PHASE 3

Phase 3 registration-directed study in females
Parallel in-trial Phase 2 component to further assess PRO endpoints in the Phase 3 portion of the study.
Study is actively enrolling

The safety and efficacy of these product candidates have not been established. None of these product candidates have been approved by the U.S. Food and Drug Administration or any other regulatory authority. There is no guarantee that any product candidate will receive regulatory approval or be successfully commercialized.

Beyond VDPHL01, we have utilized our real-world experience as dermatologists to generate a compelling portfolio of pipeline assets including exploratory assets in alopecia areata, common warts, and molluscum contagiosum, that may be advanced in the future.